NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025

A. Dimitrios Colevas(Cancer Institute (WIA)), Anthony J. Cmelak(Breast Cancer Research Foundation), David G. Pfister(Memorial Sloan Kettering Cancer Center), Sharon A. Spencer(University of Colorado Cancer Center), Douglas Adkins(Barnes-Jewish Hospital), Andrew C. Birkeland(UC Davis Comprehensive Cancer Center), David M. Brizel(Cancer Institute (WIA)), Paul M. Busse(Massachusetts General Hospital), Jimmy J. Caudell(Moffitt Cancer Center), Greg Andrew Durm(Indiana University Melvin and Bren Simon Comprehensive Cancer Center), Carole Fakhry(Sidney Kimmel Cancer Center), Thomas J. Galloway(Fox Chase Cancer Center), J.L. Geiger(Cleveland Clinic), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Christine M. Glastonbury(UCSF Helen Diller Family Comprehensive Cancer Center), Robert I. Haddad(Dana-Farber Brigham Cancer Center), Wesley L. Hicks(Roswell Park Comprehensive Cancer Center), Ying J. Hitchcock(University of Utah), Antonio Jimeno(University of Colorado Cancer Center), Aditya Juloori(University of Chicago Medicine Comprehensive Cancer Center), Michael Kase(University of Colorado Cancer Center), Debra S. Leizman(Cleveland Clinic), Ellie Maghami(City Of Hope National Medical Center), Loren K. Mell(UC San Diego Health System), Bharat B. Mittal(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Harlan A. Pinto(Cancer Institute (WIA)), Katharine A. Price(WinnMed), James W. Rocco(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Cristina P. Rodriguez(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), David A. Schwartz(University of Tennessee Health Science Center), Jatin P. Shah(Memorial Sloan Kettering Cancer Center), David J. Sher(Southwestern Medical Center), Maie A. St. John(University of Colorado Cancer Center), He Wang(Yale Cancer Center), Gregory S. Weinstein(University of Pennsylvania), Francis P. Worden, Justine Y. Bruce(University of Wisconsin Carbone Cancer Center), Sue S. Yom(UCSF Helen Diller Family Comprehensive Cancer Center), Weining Zhen(Susan Thompson Buffett Foundation), Sarah Montgomery(National Comprehensive Cancer Network), Susan Darlow(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
February 1, 2025
10.6004/jnccn.2025.0007
Cited by 123

Abstract

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses, as well as occult primary cancer, salivary gland cancer, and mucosal melanoma (MM). The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's most recent recommendations regarding management of nasopharynx cancer and ongoing research in this area.

Related Papers

No related papers found

Powered by citation graph analysis